Revvity, Inc. (RVTY) is a Technology stock trading at $140.17 (as of 2026-09-15), with a market capitalization of $15.64B and a trailing P/E of 65.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Revvity, Inc. develops products and services for diagnostics and life sciences, including instruments, reagents, assay platforms, and related software and informatics for research, analytical testing, and early detection of genetic and infectious disease. It operates through Discovery & Analytical Solutions and Diagnostics segments, serving customers worldwide across laboratory, research, and applied analysis markets.
Revvity sells laboratory instruments, reagents, software, and contract testing to life sciences researchers and diagnostic labs, collecting one-time instrument revenue plus recurring consumable and service fees. Revenue splits roughly 50/50 between Discovery and Analytical Solutions and Diagnostics, with the latter driven by reproductive health and infectious disease testing for public health customers.
Each instrument sale seeds a recurring reagent and software annuity on the installed base, while Diagnostics adds public health contract revenue, but the roughly 12% operating margin (against 57% gross) means the profit model stays exposed to pharma and biotech R&D spending cycles.
| Life Sciences | $0.4B |
| Diagnostics | $0.3B |
Business quality (Mixed): Mixed. The 117% FCF conversion and recurring revenue mix are strong, but the 12% operating margin and one-time tariff benefit in Q2 EPS signal the profitability base is narrower than the top line suggests.
Valuation: At 77× earnings, RVTY trades 48% above the Measuring & Control Equipment average (52×).
| Price | $140.17 |
| Market Cap | $15.64B |
| P/E Ratio | 65.8 |
| EV / EBITDA | 23.3 |
| Price / Book | 2.16 |
| Price / Sales | 5.37 |
| Dividend Yield | 0.2% |
| FCF Yield | 3.6% |
| DCF Value (model) | $48.41 |
| DCF Upside vs Price | -65.5% |
| Revenue (TTM) | $2.86B |
| Net Margin | 8.4% |
| Return on Equity | 3.3% |
| Debt / Equity | 0.44 |
| Current Ratio | 1.80 |
| Revenue Growth (YoY) | 1.3% |
| EPS Growth (YoY) | 2.2% |
| FCF Growth (YoY) | 56.7% |
| Altman Z-Score | 3.03 (safe) |
| Stock P/E | 65.8 |
| Sector P/E (Technology) | 30.8 |
| Industry P/E (Measuring & Control Equipment) | 43.9 |
| vs Sector | 113.6% |
| vs Industry | 50.1% |
| Top Institutional Holder | T. Rowe Price Investment Management, Inc. ($2.03B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Technology |
| Industry | Measuring & Control Equipment |
| CEO | Prahlad R. Singh |
| Employees | 11,000 |
| Country | US |
| IPO Date | 1965-07-06 |
Data as of 2026-09-15.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.